Galectin Therapeutics Inc (GALT)
1.13
-0.07
(-5.83%)
USD |
NASDAQ |
Jan 08, 16:00
1.145
+0.02
(+1.33%)
After-Hours: 20:00
Galectin Therapeutics SG&A Expense (Quarterly): 1.471M for Sept. 30, 2024
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Alaunos Therapeutics Inc | 1.007M |
| SELLAS Life Sciences Group Inc | 2.967M |
| Oragenics Inc | 1.558M |
| Anavex Life Sciences Corp | 2.781M |
| Phathom Pharmaceuticals Inc | 76.10M |